Clinical effect of etoposide combined with nedaplatin in the treatment of patients with advanced ovarian cancer and its effect on prognosis and QOL score
Clinical effect of etoposide combined with nedaplatin in the treatment of patients with advanced ovarian cancer and its effect on prognosis and QOL score
Objective:To explore the clinical effect of etoposide combined with nedaplatin in the treatment of patients with ad-vanced ovarian cancer and its effect on prognosis and QOL score.Methods:66 patients with advanced ovarian cancer from June 2022 to May 2023 in our hospital were randomly divided into two groups,33 cases in each group.The control group received et-oposide combined with cisplatin,the study group received etoposide combined with nedaplatin.The short-term efficacy,adverse reactions,quality of life(QOL)score and prognosis were compared between the two groups.Results:Compared with the control group,the total effective rate,psychological status,body function and self-care QOL score and survival rate were higher in the study group(P＜0.05),there was no significant difference in the incidence of nausea and vomiting in the study group(P＞0.05),and the incidence of adverse reactions such as neurotoxicity,hair loss,and the recurrence rate and mortality rate were lower(P＜0.05).Conclusion:The application of etoposide combined with nedaplatin chemotherapy in patients with advanced o-varian cancer can effectively reduce the incidence of adverse reactions,ensure the safety of patients during treatment,improve the prognosis of patients and improve their quality of life,has a significant short-term efficacy.
维普
万方数据